ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026
Clinical Qualification of Subcutaneous Injection Devices for Monoclonal Antibodies.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy Volunteers.Clinical pharmacology in drug development · 2026Trial
- From Small Data to Big Decisions: How Clinical Pharmacology Shapes Rare Disease Development.Journal of clinical pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous autoinjectors serve as a convenient and user-friendly alternative to manual injection using prefilled syringes or handheld syringes, enhancing self-administration in decentralized care settings, patient compliance, and dosing accuracy. Autoinjectors consistently penetrate the skin to the same depth, and are, thus, expected to reduce variability in injection conditions as compared to more operator-dependent manual self-injection. Even with an established autoinjector platform, molecule-specific technical development requirements often preclude the availability of the automated device at the start of pivotal clinical studies. This necessitates manual injections during these studies and frequently subsequent pharmacokinetic comparability studies to transition to the autoinjector. A proposed Molecule-Independent Device Bridging Approach (MIDBA) aims to eliminate the need for dedicated pharmacokinetic comparability studies for each new monoclonal antibody developed with a previously validated autoinjector platform by referring to PK data from other mAbs with dosing volumes up to 2 mL. The rationale for this approach lies in the slow absorption rates of mAbs following SC injection, which is primarily influenced by the residence time in subcutaneous tissue and subsequent lymphatic drainage rather than the specifics of the injection method. A narrative review of clinical data from 29 pharmacokinetic comparability studies revealed that independent of the molecule and the injection device, comparable pharmacokinetic and tolerability profiles were achieved following manual and automated injection. The review supports the applicability of the MIDBA as a streamlined development pathway for autoinjector validation without molecule-specific pharmacokinetic studies. This framework is expected to present a novel methodology for efficient transition from manual to automated subcutaneous injections for biotherapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.